Stock Alert: Aptinyx Hits New 52-week High

(RTTNews) - Shares of Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company, are surging almost 55 percent or $2.00 in Tuesday's morning trade at $5.66, after touching a new 52-week high of $6.47.

Monday, Aptinyx announced positive results from a phase II study of its novel NMDA receptor modulator, NYX-783, in 153 patients with post-traumatic stress disorder or PTSD. In the study, NYX-783 demonstrated statistically significant and clinically meaningful efficacy results as well as a favorable adverse event and tolerability profile.

The company said that based on these results, it expects to initiate a pivotal study in 2021.

Aptinyx has traded in a range of $1.60 to $6.47 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More